Oxadiazole replacement of an amide linkage in an RARα agonist template 1, followed by lead optimisation, has produced a highly potent and selective RARβ agonist 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl) benzoic acid (10) with good oral bioavailability in the rat and dog. This molecule increases neurite outgrowth in vitro and induces sensory axon regrowth in vivo in a rodent model of avulsion and crush injury, and thus has the potential for the treatment of nerve injury.
Oxadiazole replacement of an amide linkage in an RARα agonist template 1, followed by lead optimisation, has produced a highly potent and selective RARβ agonist 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl) benzoic acid (10) with good oral bioavailability in the rat and dog. This molecule increases neurite outgrowth in vitro and induces sensory axon regrowth in vivo in a rodent model of avulsion and crush injury, and thus has the potential for the treatment of nerve injury.
There are no effective treatments for nerve injuries including spinal cord injuries (SCI), stroke, and peripheral nerve injuries. However it has been shown 1 that stimulating the retinoid signalling pathway in animal models of nerve injury leads to axonal outgrowth and functional recovery. This pathway is activated by retinoic acid (RA) binding to retinoic acid receptors (RAR) that acts in the nucleus to drive the synthesis of RNA and hence produce proteins for axonal outgrowth. Corcoran et al. 2 have shown that RARβ signalling is required for retinoid mediated neurite outgrowth of neurons. In contrast, signalling by RARα, RARγ or the RXRs has no effect on this action. It has been shown 3 that the RARβ agonist, CD2019, can activate the RARβ receptor in a dose dependent manner. This initiates axonal outgrowth in models of nerve injury and leads to functional recovery. However CD 2019 is a highly lipophilic compound that is not significantly orally bioavailable and shows only weak to moderate selectivity over RARα and RARγ receptors. AG 261066, more recently described as a selective RARβ agonist is less potent than CD 2019 and less selective than the latter over RARα (Table 4) . Our aim was to identify a more drug-like, highly potent and selective RARβ agonist that was orally bioavailable and which had the potential to be useful in the treatment of nerve injury.
Recently, we discovered a novel and selective RARα agonist 4-[(3,5-dichloro-4-ethoxybenzoyl)amino]benzoic acid 1. This template was the basis of a lead optimisation exercise which led to an orally bioavailable and highly potent RARα agonist with high selectivity against RARβ and RARγ. 4 As part of this exercise, it was decided to modify the amide linkage between the two rings by replacing it with a variety of 5-membered heterocycles (Table 1) . Changing the amide linkage in 1 to thiazole and imidazole gave derivatives 2 and 3 that were weakly active as RARα agonists, but were more potent than amide 1 as RARβ agonists, although only weakly selective for RARβ vs RARα. The oxazole 4 was > 40-fold more potent than 1 as an RARβ agonist and had similar agonist potency for all three subtypes. Surprisingly however, increasing the number of heteroatoms in the heterocyclic ring to give the oxadiazole 5 resulted in a highly potent RARβ agonist and that had 12-and 19-fold selectivity as an agonist over RARα and RARγ respectively. This RARβ agonist selectivity and potency was lost when the isomeric 1,2,4-oxadiazol-5-yl benzoic acid derivative 6 and the 1,3,4-oxadiazol-2-yl benzoic acid compound 7 were examined.
To 6 and the 4-trifluoromethyl-7-fluorobenzofuran ring found in E6060, 7 were investigated.
Relative to 5, derivative 8 lost > 2700-fold in potency as a RARβ agonist whilst retaining most of its potency at RARα. Compound 9 which retained good RARβ agonist potency, lost all RARβ selectivity and was essentially a potent pan-RAR agonist having a similar potency at all three subtypes. In contrast, the 4,7-dimethylbenzofuran derivative 10 maintained a similar potency and selectivity profile to 5 and as we were keen to move away from the dichlorophenyl motif found in a number of herbicides, this now became our lead compound.
Compared to our lead 10, the 4-trifluoromethyl-7-fluorobenzofuran 11 and the benzothiophene 12 analogues, are less RARβ/RARα selective while the benzoxazole derivative 13 is less potent as a RARβ agonist (Table 2) .
In an attempt to increase further the selectivity and agonist potency of compound 10, a series of substitutions in the benzoic acid portion of the template were investigated ( Table 3 ). The 2-fluoro compound 14 had a similar level of potency to 10 but lost some RARβ selectivity (Table 3 ) when compared to 10. The 2-methyl 15, 3-fluoro 16 and 3-methyl 17 derivatives all lost considerable potency as RARβ agonists when compared to 10.
With this information and other data not shown, it became apparent that substitution in the benzoic acid ring in this series did not increase potency at RARβ, which is in contrast to observations made in the analogous RARα agonist series. 4 The lead RARβ agonist 10 has a high potency at RARβ (similar potency to ATRA) and behaves as a full agonist. It has a selectivity for RARβ over RARα of 13-fold, while selectivity for RARβ over RARγ is 5.6-fold.
Comparison of 10 with the selective RARβ agonist AC-261066 8 showed that in our hands, 10 is a more potent and selective RARβ agonist (Table 4) . Whilst compound 10 is marginally less potent than CD 2019, it has a better selectivity for RARβ over RARα and RARγ and is over two orders of magnitude less lipophilic. The more drug-like template present in 10 translates into a good in vitro and in vivo profile for this RARβ agonist (Table 5 ). In comparison to the mouse transactivation data shown in Table 4 , we also confirmed that 10 had a similar RARβ potency (EC 50 = 2.05 nM), similar fold selectivity for RARβ over RARα (23 fold) and for RARβ over RARγ (5 fold) against the human RAR ligand-binding domains, 4 before further predevelopment studies were investigated. The potential drug candidate 10 has excellent physico-chemical properties. It is sufficiently water soluble (> 100 µM as the sodium salt) and showed good permeability. The efflux ratios obtained from bi-directional permeability tests was close to unity indicating that 10 is likely not a PGP substrate. With no significant inhibition IC 50 > 25 μM against five Cyp450 isozymes (1A2, 2C9, 2C19, 2D6, 3A4), a human and mouse plasma protein binding of 98% and 95% respectively and showing very high stability in human microsomes, this compound was progressed to pharmacokinetic studies.
As shown in Table 6 compound 10 was found to possess a promising pharmacokinetic profile in both rat and dog. It demonstrated a low rate of blood clearance, a moderate half-life and good oral bioavailability. It was also found to penetrate the CNS, with nearly equivalent amounts detected in brain tissue when compared to plasma, 8 h after dosing orally to rats.
In the HEPG2 cell toxicity assay 10 was found to be completely devoid of alerts at the highest concentration tested (50 μM). Furthermore, in a binding assay for HERG channels, the compound, demonstrated no inhibition at 10 μM. Genetic toxicity testing of the material showed that it was inactive in bacterial cytotoxicity tests up to 100 μM and in an Ames test in three bacterial strains. Similar, negative results were obtained in an in vitro micronucleus test in CHO-K1 cells, in both the presence and absence of S9.
Synthesis and characterisation of compounds in Tables 1-3 have  been described 10 and involve standard preparation of the 5-membered heterocyclic rings. This is illustrated by the preparation of our lead oxadiazole 10 outlined in Scheme 1. Compound 10 was evaluated for neurite outgrowth/branching in cerebellar cultures. Cerebellar cultures grown on a monolayer of CHO-MAG were treated with RARβ agonists and neurite outgrowth was assessed by immunostaining and neurite length quantification. 10 The compound increased neurite length in a dose dependant manner ( Fig. 1) and thus has the potential to be useful in the treatment of nerve injury. The novel RARβ agonist 10 has also been demonstrated to be capable of inducing sensory axon regrowth in vivo in a rodent model of avulsion as shown in Fig. 2 , where avulsion is defined as the traumatic tear of nerve roots from the spinal cord causing injury. Rats were trained for two weeks prior to surgery in behavioural tasks and scores were recorded the day before surgery, the day after surgery and then weekly, for four weeks. Surgery was performed as previously described. 11, 12 In a sticky tape task, the time taken to sense and remove the tape from the paw of the lesioned forelimbs was measured. From week three of treatment, significantly lower latencies were observed with the injured forelimbs of compound 10 treated rats (3 mg/kg, po) compared to vehicle treated ones. In locomotor tasks, the number of foot slips in a horizontal ladder made by the injured forelimb of the compound 10 treated rats was also measured. This parameter was found to be markedly lower than that of vehicle treated rats from week two. Further details and data on an in vivo model of crush injury will be presented in due course. In summary, replacing the amide linkage between the two aromatic rings in our selective RARα agonist template with 5-memebered heterocycles, gave compounds which were selective as RARβ agonists. SAR exploration of the oxadiazole based series led to potent and selective RARβ agonists. In particular compound 10, which will henceforth be referred to as C286, possesses favourable physicochemical properties with an oral bioavailability of > 40% in both rats and dogs, a good overall PK profile and drug-like properties. Furthermore, it has been shown to be inactive in cytotoxicity and genotoxicity screens. It has also been demonstrated here to increase neurite outgrowth in vitro and induce sensory axon regrowth in vivo in a rodent model of avulsion and crush injury and thus warrants further consideration as a potential therapeutic agent for the treatment of nerve injury.
